MetaCap

Neuropace (NPCE) vs Profound Medical (PROF)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Profound Medical (PROF) has outperformed Neuropace (NPCE) over the past year, gaining 6.2% versus a loss of 44.6%. Over five years, NPCE leads with a -32.8% price change compared with -43.6% for PROF. Neuropace is the larger company by market cap ($273.9 million vs $233.7 million), about 1.2 times the size, while Profound Medical is growing revenue faster (+50.7% vs +25.1%).

Neuropace converts more of its revenue into profit, with a net margin of -21.5% versus -264.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NPCE-44.60%PROF+6.16%
+48%-2%-52%
Nov 21, 20251 yearNov 20, 2026
NPCE-32.91%PROF-47.62%
+62%-17%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NPCE versus PROF key metrics
MetricNPCEPROF
Share price$7.95$6.38
Market cap$273.89M$233.68M
1-day change-2.33%-3.19%
YTD return-48.51%-18.93%
1-year return-44.60%+6.16%
5-year return-32.80%-43.64%
EPS (TTM)$-0.56$-0.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$99.99M$16.10M
Revenue growth (YoY)+25.13%+50.73%
Net income (latest FY)$-21.46M$-42.57M
Gross margin77.23%70.77%
Operating margin-16.34%-256.27%
Net margin-21.47%-264.44%
52-week high$19.60$8.95
52-week low$5.46$4.80
Distance from 52-week high-59.44%-28.72%
Analyst consensusbuystrong_buy
Avg. price target upside+53.71%+74.61%
Average volume270.76K208.29K
Shares outstanding34.45M36.63M
Employees216162
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PROF has outperformed NPCE by 50.8 percentage points over the past year.
  • Neuropace is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -264.4 cents for Profound Medical.
  • Profound Medical grew revenue faster in its latest fiscal year (+50.73% vs +25.13%).

About Neuropace

NPCE stock →

NeuroPace, Inc. operates as a medical device company in the United States.

Health Care · Medical/Dental Instruments · 216 employees

About Profound Medical

PROF stock →

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.

Health Care · Medical/Dental Instruments · 162 employees

NPCE vs PROF FAQ

Which is bigger, Neuropace or Profound Medical?

Neuropace (NPCE) is larger, with a market capitalization of $273.89M compared with $233.68M for Profound Medical (PROF).

Which stock has performed better over the past year, NPCE or PROF?

PROF returned +6.16% over the past 12 months, compared with -44.60% for NPCE (price return, excluding dividends). Past performance does not predict future results.

Are Neuropace and Profound Medical in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons